Robert Barrow

MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Robert Barrow Recent News

MindMed Converts Shares To Have A Single Class
Psychedelics-focused biopharma company Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), (DE:MMQ) confirmed Wednesday that all the company’s issued and outstanding multiple voting shares will undergo a mandatory conversion into subordinate voting shares in accordance with the company&rsq
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15.
MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years
MindMed (NASDAQ: MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog.
Why Mind Medicine Shares Are Rising Today
Mind Medicine Inc (NASDAQ: MNMD) is trading higher Tuesday morning after the company announced the U.S.
Cannabis Movers & Shakers: MindMed, Halo Collective, Item 9, PSYC, Flora Growth
Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc (NASDAQ: MNMD) announced on Friday that Stephen Hurst has resigned from his role as director of the company's board.
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
On Tuesday, Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use d
Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams
MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a psychedelic-based biotech company, announced Wednesday that Bradford Cross, its chief technology officer, has transitioned from his role.
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
MindMed (NASDAQ: MNMD) (NEO: MMED), 
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder.
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors.
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn.
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced recently that it has tapped Maria A. Oquendo, M.D., Ph.D. to its scientific advisory board.
Cannabis Movers & Shakers: Leafly Holdings, Linneo Health, Flowhub, MindMed
Leafly Holdings Taps Suresh Krishnaswamy As New CFO
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
A psychedelics-focused medicine company MindMed (NASDAQ: MNMD) reported Monday that has been added to the FTSE Russell 3000 index, effective June 25th. The FTSE Russell 3000 index measures the performance of the 3,000 largest companies in the United States.
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R.
J.R. Rahn Steps Down As MindMed CEO
Mind Medicine Inc. (NASDAQ: MNMD), more commonly known as MindMed, has announced co-founder and chief executive J.R. Rahn is stepping down from his leadership role, effective immediately.
Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify
Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.